Publish or Perish: Creating Value through Publications
Publish or Perish: Creating Value through Publications
JLABS @ LabCentral , 700 Main Street , Cambridge , MA 02139
April 20, 2017 from 17:30 PM to 21:00 PM (EST)
$10 - $35
In order to succeed, biotech, drug, and device companies must publish their results in peer-reviewed journals in an effort to add value to promote and commercialize their technologies. The drivers of this exercise include reimbursement, credibility, commercialization and valuations. If you’re not publishing, you’re missing out on valuable opportunities to improve the chances for your company to succeed.
In this interactive program, you will learn the how, why and when of a successful publication strategy. Experts in the field will be joined by professionals who have effectively implemented the process. You will learn from their successes and failures.
Topics to be covered:
- When, where and what to publish
- Timing of publications throughout the product development cycle
- Article types to consider, and why; look at both home runs and base hits
- How peer-reviewed publications support reimbursement strategy
- Developing a roadmap to maximize publication objectives
- PR and your publication program
The program will include case examples and a sample roadmap for success.
Joel Batts | Partner, Telos Partners, LLC read bio»
Samir Bhattacharyya | Head, Health Economics and Market Access, US Depuy Synthes read bio»
Tom Michal | VP of Market Access, Health Economics & Reimbursement, intrinsic Therapeutics, Inc. read bio»
Laurie Myers | Head, Marketing, Fidia Pharma US Inc. read bio»
3:30 PM | Registration and Networking
4:00 PM | Presentation
4:30 PM | Q&A
5:00 PM | Panel Discussion
5:45 PM | Q&A
6:00 PM | Food and Networking
7:00 PM | Program Close
$25 | General Public
$15 | Student/Academic
$45 | At the door
JLABS @ LabCentral
700 Main Street
Joel Batts, MA | Partner at Telos Partners, LLC
Joel is a medical device industry veteran, with 20 years of leadership experience developing scientific and regulatory strategies for start-ups to large cap companies. He has delivered >$100 million return on investment by delivering FDA approvals for Class II and Class III devices in the musculoskeletal and wound care spaces. He has published and presented the results of pre-clinical and clinical science in journals such as American Journal of Sports Medicine, American Journal of Orthopaedics, and venues such as the American College of Foot and Ankle Surgeons. In 2010, he led a business development team in the application of a novel biologic material to osteoporotic patients for reducing the incidence of hip fractures. After conducting early-phase trials and developing the scientific and regulatory, the team sold the technology for $30 million. He has also overseen key areas of investment and integration for four major acquisitions. Outside of Telos Partners, Joel is part of a LifeNet International, a non-profit that is transforming healthcare in African communities. Joel earned a BS in exercise science from the University of Florida and an MA in bioethics and health policy from Loyola University Chicago.
Connect with Joel:
Samir Bhattacharyya, PhD, MS, MSc | Head, Health Economics and Market Access, US Depuy Synthes
Dr. Samir Bhattacharyya has 19 years of global experience in the medical device, pharmaceutical, and biotechnology industries. He held leadership positions with increasing responsibilities in sales & marketing, pricing & reimbursement, health economics & market access, and clinical research & development. Dr. Bhattacharyya has built and led best-in-class functions and teams in companies experiencing major growth. Prior to joining Johnson & Johnson, Dr. Bhattacharyya was a Vice President of Market Access Services at Covance. Prior to joining Covance, Samir was a senior director of marketing at Baxter Healthcare Corporation. Dr. Bhattacharyya also worked for Amgen, Pfizer (Pharmacia), and Procter & Gamble.
Dr. Bhattacharyya’s therapeutic experience includes orthopedic, nephrology, oncology, cardiovascular, sports medicine, urology, and infectious diseases. He has many publications in peer reviewed journals in the field of health economics and outcomes research.
Dr. Bhattacharyya received his PhD in Pharmacoeconomics from the University of Arizona Pharmacy School and MS in Economics from the Eller College of Management at the University of Arizona.
Tom Michal | VP of Market Access, Health Economics & Reimbursement, intrinsic Therapeutics, Inc.
Tom has over 2 decades of healthcare experience with an emphasis on market access, health economics, global reimbursement, and government relations. He is a recognized expert in coding, coverage, and payment initiatives in start-up environments, as well as enterprise-level biomedical firms. As a specialist in market access and early commercialization, Tom has been responsible for guiding company efforts in key global markets in an effort to drive innovative technology adoption. Prior to joining Intrinsic Therapeutics, Tom has held leadership positions with multi-national corporations, as well medical device start-ups – these organizations include: Smith & Nephew Endoscopy, Moximed Inc., Allina Health Systems, and Deloitte Consulting. Tom completed his undergraduate work at the University of Massachusetts Amherst, obtaining a Bachelor of Science Degree. He later earned a Master’s in Business Administration from Rice University in Houston Texas, with a concentration in both Marketing and Finance.
Laurie Myers, PhD MBA | Head, Marketing, Fidia Pharma US Inc.
Dr. Myers is a pharmaceutical executive, entrepreneur and scientist whose expertise traverses all aspects of branded specialty product life cycle management, from early discovery through product launch, including FDA submissions, P&L responsibilities and creating, disseminating and realizing global marketing plans. Dr. Myers therapeutic expertise includes oncology, cardiovascular disease/thrombosis and osteoarthritis with additional aptitude in infectious disease, neurology/psychiatric disorders, asthma, urologic disease and women's health. She has played key role in drug development, marketing and commercialization for leading global pharmaceutical companies, including Novartis, Aventis, DuPont, Pfizer and Sanofi which included leadership positions in both R&D and marketing. She has been named to the Top 100 Brand Champions by Pharma Voice.
Dr. Myers is a founding member of the Cingulate Therapeutics Board of Directors and has contributed to two investor organizations; Mid Atlantic Bio Angels and Mid Atlantic Diamond Ventures and was commercial advisor to another start-up , EpiGen Pharma. She is a team-focused change agent with a reputation for building strong teams, successfully merging scientific and corporate cultures.
Dr. Myers earned her PhD in Toxicology from Rutgers Medical School/Rutgers School of Pharmacy in New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia, PA. She has served as Adjunct Professor at The College of New Jersey School of Business. Her current position is Head of Marketing at Fidia Pharma US Inc. in Parsippany NJ.